Department of Defense (DOD) Sponsored U.S. Study Met Primary Endpoint for Improvement in Oxygenation and Demonstrated Treatment with Inhaled Leukine Was Safe and Well Tolerated

Lexington, MA – June 28, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced top-line results of the U.S.-based iLeukPulm clinical trial of inhaled Leukine (sargramostim, yeast-derived recombinant human granulocyte macrophage colony stimulating factor (GM-CSF)) in hospitalized COVID-19 patients (NCT04411680).¹  This prospective, randomized, controlled, open-label study was conducted at 11 U.S. hospitals.  The ...